Our Vision and Mission
Our vision is to provide a healthier tomorrow for our companions today. We are driven by our mission, that through dedication,
innovation and cutting-edge research, be on the frontier in the fight against pet obesity.
The Problem
Pet obesity has reached critical levels, with around 1 in 5 to 1 in 4 of our companions are estimated to be clinically obese, and between 40% to 60% are considered overweight. Obesity and overweight reduce the lifespan by up to 2.5 years and is a primary driver for osteoarthritis, diabetes, and cardiovascular disease.
The Science
We at Prodessa Pharmaceutical aim to develop our flagship molecule, K161, a pan-SHIP1/2 inhibitor, to become the leading therapeutic in the fight against obesity in companion animals. In preclinical small animal trials, K161 achieved a 20–25% weight reduction without appetite suppression, change in diet or enhanced physical activity. Unlike appetite suppressants such as GLP-1 agonists, K161 reduces chronic inflammation and improves oxidative metabolism to promote leanness and preserve muscle mass.